Arkolith/Insider Trading/RXRX/Form 4

Gibson Christopher

DirectorRECURSION PHARMACEUTICALS, INC. (RXRX) · full profile →Form 4 · filed Mar 11, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 9, 2026Conversion(C)20K—$0927K
Mar 9, 2026Gift(G)20K—$0907K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 9, 2026Conversion(C)20K—$04.5M

Transaction Codes

C
Conversion of a derivative
G
Gift

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001601830-26-000049) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML